Sector pending / Pharmaceutical PreparationsUpdated 2026-05-10 22:07 UTC

LON/0JXI stock hub

LON/0JXI has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0JXIis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

8.6B

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0JXI

In the news

Latest news · LON/0JXI

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-49.3

P25 n/aP50 n/aP75 n/a

ROIC-22.8

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0JXI market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

166

Groups with data

Currency

USD

Showing 166 of 166 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	UK
Employees	915
Employees Change	387%
Employees Change Percent	73.3
Enterprise value	$8.3B
Exchange	London Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Pharmaceutical Preparations
Isin	US5588681057
Last refreshed	2026-05-10
Market cap	$8.6B
Price	$517
Price currency	USD
Rev Per Employee	937,311.85x
Sic	2834
Symbol	lon/0JXI
Website	https://www.madrigalpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-2.72%
EV Earnings	-35.37x
EV/FCF	-40.18x
EV/Sales	9.97x
FCF yield	-2.39%
P/B ratio	20.97x
P/S ratio	10.06x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-27.68%
EBITDA Margin	-27.55%
Gross margin	93.07%
Gross Profit	$798.2M
Gross Profit Growth	243.73%
Gross Profit Growth Q	114.33%
Net Income	$-234.3M
Pretax Margin	-27.32%
Profit Margin	-27.32%
Profit Per Employee	$-256,107
ROA	-17.62
Roa5y	-42.5
ROCE	-35.26
ROE	-49.35
Roe5y	-101.6
ROIC	-22.77

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	77.46%
Cagr3y	19.75%
Cagr5y	31.56%
Revenue Growth	256.82x
Revenue Growth Q	126.84x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$1.02
Assets	$929.5M
Cash	$615.5M
Current Assets	$867.2M
Current Liabilities	$248.1M
Debt	$263M
Debt Equity	$0.64
Debt FCF	$-1.27
Equity	$411.6M
Interest Coverage	-11.68
Liabilities	$517.9M
Long Term Assets	$62.2M
Long Term Liabilities	$269.8M
Net Cash	$352.5M
Net Cash By Market Cap	$4.08
Net Cash Growth	-35.65%
Net Debt Equity	$-0.86
Tangible Book Value	$406M
Tangible Book Value Per Share	$17.62
WACC	-1.08

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.5
Inventory Turnover	0.94
Net Working Capital	$25M
Quick ratio	2.96
Working Capital	$639.2M
Working Capital Turnover	$1.03

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	2.67%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	77.39%
200-day SMA	471.8
3Y total return	71.72%
50-day SMA	489
50-day SMA vs 200-day SMA	50over200
5Y total return	294.02%
All Time High	610.6
All Time High Change	-14.48%
All Time High Date	2025-12-24
All Time Low	57.67
All Time Low Change	805.5%
All Time Low Date	2022-01-31
ATR	23.13
Beta	-1.05
Ch YTD	-11.28
High	540
High52	610.6
High52 Date	2025-12-24
High52ch	-15.34%
Low	517
Low52	264.1
Low52 Date	2025-05-27
Low52ch	95.73%
Ma50ch	6.79%
Price vs 200-day SMA	10.69%
RSI	52
RSI Monthly	61.2
RSI Weekly	57.72
Sharpe ratio	1.16x
Sortino ratio	2.14
Total Return	2.67%
Tr YTD	-11.28
Tr1m	2.08%
Tr1w	1.06%
Tr3m	8.25%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-237.4M
Operating margin	-27.68

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	12,606,401%
Net Borrowing	167,487,652.7
Shares Insiders	8.43%
Shares Institutions	70.57%
Shares Qo Q	27.17%
Shares Yo Y	-2.67%
Short Ratio	11.46

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-290.5M
Average Volume	60.35x
Bv Per Share	17.86
CAPEX	$-3.3M
Ch1m	2.08
Ch1w	1.06
Ch1y	77.39
Ch3m	8.25
Ch3y	71.72
Ch5y	294
Ch6m	8.67
Change	-1%
Change From Open	-1.15
Close	522.2
Days Gap	0.15
Depreciation Amortization	1,109,806.7
Dollar Volume	15,508.8
Earnings Date	2026-05-06
EBIT	$-237.4M
EBITDA	$-236.3M
EPS	$-10.34
F Score	2
FCF	$-206.3M
FCF EV Yield	-2.49x
Financing CF	189,078,611
Fiscal Year End	December
Founded	2,016
Investing CF	45,917,674
Is Primary Listing	0
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Ma150	499.4
Ma150ch	4.57%
Ma20	521.7
Ma20ch	0.1%
Net CF	32,974,574
Open	523
Position In Range	0
Ppne	10,443,772.3
Price Date	2026-05-08
Ptbv Ratio	21.25
Relative Volume	0.5x
Revenue	857,640,339x
SBC By Revenue	9.82x
Share Based Comp	84,225,190
Tr6m	8.67%
Volume	30
Z Score	6.61

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0JXI pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0JXI stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0JXI?

Insider, institutional, and short-interest positioning.

Institutional ownership

+70.6%

Share of float held by funds and institutions

Insider ownership

+8.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LON/0JXI momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.0

Neutral momentum band

Price vs 200-day MA

+10.7%

50/200-day relationship not available

Beta (5Y)

-1.04

Less volatile than the market

Sharpe ratio

1.16

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0JXI

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0JXI stock rating?

lon/0JXI is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0JXI analysis?

The full report lives at /stocks/lon/0JXI/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0JXI?

The latest report frames lon/0JXI around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0JXI page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.